Screener
Opus Genetics IRD Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Opus Genetics in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The source filing: Opus Genetics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034084
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| Loss from operations | (14,364) | (9,929) |
| Fair value change in warrant liabilities | (51,364) | 2,805 |
| Financing costs | (582) | (1,372) |
| Interest expense | (69) | — |
| Other income, net | 844 | 302 |
| Loss before income taxes | (65,535) | (8,194) |
| Benefit (provision) for income taxes | — | — |
| Net loss | (65,535) | (8,194) |
Item 1. Financial Statements
FAQ
- What is Opus Genetics's interest expense?
- Opus Genetics (IRD) reported interest expense of $69K in Q1 2026.
- What is the long-term trend for Opus Genetics's interest expense?
- Over 4 years (2021 to 2025), Opus Genetics's interest expense has grown at a 183.4% compound annual growth rate (CAGR), from $2K to $129K.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about Opus Genetics's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude